Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Valion Bio (VBIO) Stock Price & Analysis

175 Followers

VBIO Stock Chart & Stats

$0.51$0.01(1.39%)
At close: 4:00 PM EST
$0$2.5$5$7.5Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$0.48 - $0.51
52-Week Range
$0.47 - $67.50
Previous Close
$0.50
Volume
N/A
Average Volume (3M)
2.96M
Market Cap
$1.10M
Enterprise Value
$24.70M
Total Cash (Recent Filing)
$2.11M
Total Debt (Recent Filing)
$17.41M
Price to Earnings (P/E)
―
Beta
2.46
Next Earnings
Nov 13, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Traction And Gross Margin

Revenue traction and positive gross margin indicate that Valion Bio has begun generating commercial activity with some underlying unit economics. If revenue scales beyond its currently low base, this foundation could support improved operating leverage and strengthen the company’s ability to fund development.

Low Financial Leverage

Very low debt relative to equity and total assets gives Valion Bio a comparatively conservative leverage position. This reduces near-term interest and refinancing pressure, preserves flexibility for development spending, and provides a stronger balance-sheet base than a similarly loss-making company with substantial borrowings.

Government-supported Lead-candidate Development

Government-supported evaluation of Entolimod advances the lead candidate’s countermeasure development while preserving company capital. Positive safety findings and testing of post-exposure efficacy could improve development credibility and expand future partnership or government-commercialization opportunities.

Bears Say

Severe Operating Losses And Cash Burn

Persistent cash burn means current operations are not self-funding and continued losses can erode the equity base over time. The large gap between revenue and operating costs also limits internal investment capacity, increasing dependence on external financing while development programs mature.

Dilutive Financing And Future Cash Claims

Repeated preferred-stock financings provide liquidity but increase potential dilution and give investors claims on future economics. The ten-year revenue royalty can reduce cash retained from commercialization, while warrant and conversion features may constrain shareholder returns as funding needs continue.

Leadership Turnover And Execution Risk

Departures across key executive roles create continuity and execution risk during an important development and financing period. Replacing senior leadership may distract the organization, slow strategic decisions, and weaken accountability as Valion Bio advances programs and pursues partnerships.

Valion Bio News

VBIO FAQ

What was Valion Bio’s price range in the past 12 months?
Valion Bio lowest stock price was $0.47 and its highest was $67.50 in the past 12 months.
What is Valion Bio’s market cap?
Valion Bio’s market cap is $1.10M.
When is Valion Bio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Valion Bio’s earnings last quarter?
Valion Bio released its earnings results on Aug 17, 2026. The company reported -$52.537 earnings per share for the quarter.
Is Valion Bio overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Valion Bio pay dividends?
Valion Bio does not currently pay dividends.
What is Valion Bio’s EPS estimate?
Valion Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valion Bio have?
Valion Bio has 2,155,637 shares outstanding.
What happened to Valion Bio’s price movement after its last earnings report?
Valion Bio reported an EPS of -$52.537 in its last earnings report. Following the earnings report the stock price went down -4.26%.
Which hedge fund is a major shareholder of Valion Bio?
Currently, no hedge funds are holding shares in VBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology